Quick summary
The U.S. Food and Drug Administration (FDA) has announced a voluntary recall affecting specific lots of generic cetirizine hydrochloride tablets.
This recall, initiated by MedSafe Generics Inc., is due to detected levels of N-nitrosodimethylamine (NDMA) impurities.
These levels exceed the acceptable limits set by the FDA, impacting certain over-the-counter allergy relief products and prioritizing consumer safety.
What happened?
On November 15, 2023, the FDA publicly announced a Class II voluntary recall of cetirizine hydrochloride tablets, 10 mg.
The affected products were manufactured by MedSafe Generics Inc. and distributed across the U.S. This announcement followed internal quality control measures.
The recall stems from analytical testing that identified levels of N-nitrosodimethylamine (NDMA) exceeding the Acceptable Intake (AI) limit set by the FDA.
Cetirizine is an active pharmaceutical ingredient (API) widely used in over-the-counter (OTC) medications, including brand names like Zyrtec and their generic counterparts. It functions as an antihistamine, primarily offering allergy relief by treating symptoms such as sneezing, itching, watery eyes, and runny nose.
The Drug Recall Process is a structured procedure for removing a drug product from the market or correcting it. This process can be initiated voluntarily by the manufacturer or mandated by regulatory agencies like the FDA.
Adherence to FDA Regulations governs this entire process, consistently prioritizing consumer safety when products are found to be defective or potentially harmful. This robust framework helps us identify potential food intolerances in medications or other health risks.
An Active Pharmaceutical Ingredient (API) is the core component of a drug responsible for its intended therapeutic effects. Stringent quality control throughout API manufacturing is critical to prevent the inclusion of impurities like NDMA.
Why does this matter?
N-nitrosodimethylamine (NDMA) is classified as a probable human carcinogen. Long-term exposure to NDMA above acceptable levels could potentially increase cancer risk.
This recall underscores the critical importance of robust pharmaceutical quality control. It highlights the FDA's continuous role in ensuring the safety and efficacy of medications available to the public.
Given that cetirizine is an over-the-counter medication, its widespread use means many consumers could be unknowingly exposed. We urge immediate attention to this update.
Who may be affected?
Consumers in the U.S. who have purchased and used generic cetirizine hydrochloride 10 mg tablets manufactured by MedSafe Generics Inc. may be affected.
Specific lot numbers and expiration dates identify the impacted products. Many individuals rely on cetirizine for daily or seasonal allergy relief.
We advise all users of generic cetirizine products to verify their medication against the recall information provided.
What does the original source say?
The FDA's official announcement confirms the voluntary recall initiated by MedSafe Generics Inc. The pharmaceutical company made this decision after routine quality checks revealed elevated NDMA levels in certain batches.
MedSafe Generics Inc. has stated its full cooperation with the FDA to facilitate this important consumer safety measure.
The recall specifically impacts MedSafe Generics Cetirizine Hydrochloride Tablets, 10 mg. These products were sold in bottles of 30, 90, and 300 counts.
Affected Products & Lot Numbers:
- Lot: C12345, Expiration: 05/2025 (30-count bottles)
- Lot: C67890, Expiration: 08/2025 (90-count bottles)
- Lot: C11223, Expiration: 11/2025 (300-count bottles)
The primary reasons for the recall are the presence of impurities, specifically N-nitrosodimethylamine (NDMA). These levels exceeded the acceptable intake limits established by the FDA.
This situation suggests a potential manufacturing defect or contamination issue occurred within the production process of the active ingredient.
We strongly encourage readers to consult the FDA's official drug recall information and safety alerts for the most current details and comprehensive product specifications. This is our primary external link for official recall information.
For more comprehensive information about N-nitrosodimethylamine (NDMA) and its potential health implications, we recommend exploring the detailed information on N-nitrosodimethylamine (NDMA) provided by the National Institutes of Health.
Important limitations
- Evidence Limitation: This recall is specifically based on analytical testing that detected NDMA levels in particular manufacturing batches. It does not imply that all cetirizine products on the market are affected, nor does it necessarily indicate an immediate severe health risk from short-term exposure.
- Population Limitation: The immediate health risks from this recall are primarily for individuals who have consistently consumed the recalled lots over an extended period. The potential impact may vary significantly based on individual health factors, the specific dosage taken, and the overall duration of use.
- Uncertainty/Missing Information: While N-nitrosodimethylamine (NDMA) is classified as a probable carcinogen, the exact magnitude of risk from these specific recalled cetirizine products remains under evaluation. The specific length of exposure needed to incur risk is also uncertain. Consumers should prioritize and rely on official guidance from the FDA and their healthcare providers.
What should readers do?
Immediately inspect your cetirizine hydrochloride tablets. Locate the lot number and expiration date clearly printed on the bottle.
If your product matches any of the recalled lots from MedSafe Generics Inc., discontinue use immediately and securely store the product away from children.
Do not panic. If you have been taking the recalled product, contact your doctor, pharmacist, or other healthcare provider promptly. They can discuss alternative allergy relief options or address any concerns you may have.
Your healthcare provider can advise on managing any adverse effects, if experienced, and help you explore timeless natural remedies for symptom management that align with your health needs.
You may return the recalled product to the place of purchase for a full refund. MedSafe Generics Inc. has issued instructions to retailers to remove all affected products from shelves and manage consumer returns efficiently.
Stay informed by regularly monitoring the FDA's website for any further updates or expanded recall information. Understanding guidelines for managing public health concerns like drug recalls is crucial for your personal safety and informed decision-making.
For broader guidance on safe medication practices and general drug safety, refer to the CDC's guidance on medication safety.
To learn more comprehensive information about cetirizine, including proper dosage instructions and its various uses, we recommend visiting the comprehensive information about cetirizine provided by MedlinePlus (U.S. National Library of Medicine).
For the latest information regarding NDMA impurities in various medications and the FDA's ongoing efforts to address them, consult the FDA updates on NDMA impurities in medications.
Primary sources
- U.S. Food and Drug Administration (FDA). November 15, 2023. Press Release: MedSafe Generics Inc. Initiates Voluntary Recall of Cetirizine Hydrochloride Tablets Due to NDMA Impurities.
- MedSafe Generics Inc. November 14, 2023. Voluntary Recall Notice: Cetirizine Hydrochloride Tablets, 10 mg.
How we reported this story
This report was prepared from the original documents linked above. It distinguishes official guidance from early research and will be corrected under our published Corrections Policy when necessary.
Recommended
- top herbs for coughs and colds
- harnessing essential oils for wellbeing and remedies
- how essential oils can treat various conditions
- understanding mental health and illness differences
- essential oil blends for home first aid
For more up-to-date information and research, we invite you to explore our comprehensive resources. Health News and Research Updates.
Comments
Post a Comment